Atlas Trials

Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis

Clinical trial NCT04261790 · COMPLETED

Trial details

NCT number
NCT04261790
Sponsor
Johns Hopkins University
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Multiple Sclerosis, Relapsing-Remitting
Start date
2020-08-01
Primary completion
2024-10-31
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.